CIPLA LTD vs GLOBAL HEALTH LIMITED

A side-by-side comparison of CIPLA LTD (CIPLA) and GLOBAL HEALTH LIMITED (MEDANTA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs MEDANTA on 9 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
63.62
3.42
P/B ratio
9.15
0.90%
Dividend yield
0.04%
₹48.02
EPS
₹20.70

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
15.20%
15.00%
Return on capital
17.00%
21.00%
EBITDA margin
21.00%
13.71%
Net margin
12.56%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
17.62%
10.88%
Profit CAGR (3Y)
19.33%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹35,414 Cr
₹28,163 Cr
Revenue
₹4,410 Cr
₹3,862 Cr
Net profit
₹554 Cr
0.02
Debt / equity
0.30
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
GLOBAL HEALTH LIMITED
  • + ["Company has delivered good profit growth of 80.7% CAGR over last 5 years"]
  • ["Stock is trading at 9.07 times its book value"]
CIPLA LTD full analysis GLOBAL HEALTH LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

CIPLA LTD vs GLOBAL HEALTH LIMITED: Share Price, Valuation & Which to Buy | DocStoX